Blueprint Medicines Corporation (NASDAQ: BPMC), a US-based global precision therapy company that said it invents life-changing therapies for people with cancer and blood disorders, announced on Tuesday that the US Food and Drug Administration (FDA) has withdrawn a partial clinical hold on the Phase 1/2 VELA trial of BLU-222.

The company announced on 10 February 2023 that the FDA had placed a partial clinical hold on the VELA trial because of reported visual adverse events, which included transient, reversible episodes of light sensitivity and blurred vision, observed in a limited number of patients. Subjects already enrolled in the trial have continued receiving the study drug.

With the removal of the partial clinical hold, the company is working with trial sites to reinitiate patient enrolment.